Steven D. Harr

2016 - Juno Therapeutics

In 2016, Steven D. Harr earned a total compensation of $2.9M as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, a 15% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$131,840
Option Awards$2,378,863
Salary$404,954
Total$2,915,657

Harr received $2.4M in option awards, accounting for 82% of the total pay in 2016.

Harr also received $131.8K in non-equity incentive plan and $405K in salary.

Rankings

In 2016, Steven D. Harr's compensation ranked 3,298th out of 14,075 executives tracked by ExecPay. In other words, Harr earned more than 76.6% of executives.

ClassificationRankingPercentile
All
3,298
out of 14,075
77th
Division
Manufacturing
1,142
out of 5,486
79th
Major group
Chemicals And Allied Products
340
out of 1,900
82nd
Industry group
Drugs
246
out of 1,543
84th
Industry
Biological Products, Except Diagnostic Substances
51
out of 287
82nd
Source: SEC filing on April 21, 2017.

Harr's colleagues

We found four more compensation records of executives who worked with Steven D. Harr at Juno Therapeutics in 2016.

2016

Hans Bishop

Juno Therapeutics

Chief Executive Officer

2016

Hyam Levitsky

Juno Therapeutics

Chief Scientific Officer

2016

Robert Azelby

Juno Therapeutics

Executive Vice President, Chief Commercial Officer

2016

Bernard Cassidy

Juno Therapeutics

General Counsel

News

In-depth

You may also like